The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants
Abstract
BACKGROUND: Patent ductus arteriosus (PDA) and intraventricular haemorrhage (IVH) are both associated with increased mortality and morbidity in preterm infants. Indomethacin has been used successfully to treat symptomatic PDA and may also prevent or limit IVH in the neonatal period. There are however potential unwanted side effects of indomethacin, in particular a potential for reduced organ perfusion that might outweigh any clinical benefits. The prophylactic use of indomethacin, where infants who may not have gone on to develop a symptomatic PDA or IVH would be exposed to indomethacin, warrants particular scrutiny. OBJECTIVES: This review examines the effectiveness of prophylactic intravenous indomethacin in reducing the mortality and morbidity associated with PDA and IVH in preterm infants. SEARCH STRATEGY: An initial literature search was conducted in three computerised databases: MEDLINE; EMBASE; and the Oxford Database of Perinatal Trials in October 1994. The search was updated in February 1997 and October 2001. SELECTION CRITERIA: Strict selection criteria were applied to clinical trials: the population had to be newborn preterm infants (less than 37 completed weeks gestation); the intervention had to be prophylactic intravenous indomethacin; the trial had to be randomised and controlled; and at least one of several prespecified outcomes had to be reported in the results. DATA COLLECTION AND ANALYSIS: The methodological quality of each study was assessed using explicit criteria. Data on relevant outcome measures were extracted and, where appropriate, the results of individual trials were combined using meta-analysis techniques to provide a pooled estimate of effect. MAIN RESULTS: Nineteen eligible trials randomising 2872 infants were identified. There is no evidence of difference in mortality at latest follow-up between infants receiving prophylactic indomethacin and controls, pooled relative risk (RR) = 0.96 [95% CI 0.81 to 1.12]. There is no evidence to suggest prophylactic indomethacin is associated with any reduction in long-term neurosensory impairment, ie no significant difference in rates of cognitive delay, cerebral palsy, blindness or deafness. The incidence of symptomatic patent ductus arteriosus is significantly reduced in treated infants, pooled RR = 0.44 [0.38 to 0.50] but there is no evidence that treatment affects respiratory outcomes. Prophylactic indomethacin reduces the need for surgical PDA ligation [RR = 0.51 (0.37,0.71)]. Prophylactic indomethacin significantly reduces the incidence of Grade 3 and 4 intraventricular haemorrhage, pooled RR = 0.66 [0.53 to 0.82]. There is no evidence of difference in rates of necrotising enterocolitis, excessive clinical bleeding or sepsis. Increased incidence of oliguria is seen with prophylactic indomethacin [RR = 1.90 (1.45,2.47] but this is not associated with major renal impairment. REVIEWER'S CONCLUSIONS: Prophylactic treatment with indomethacin has a number of immediate benefits, in particular a reduction in symptomatic patent ductus arteriosus, the need for duct ligation and severe intraventricular haemorrhage. There is no evidence to suggest either benefit or harm in longer term outcomes including neurodevelopment. Depending on clinical circumstances and personal preferences, there may be a role for prophylactic indomethacin in some infants on some neonatal units.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Low‐dose indomethacin and prevention of intraventricular hemorrhage: A multicenter randomized trial
Ment, L. R., Ehrenkranz, R. A., Duncan, C. C., Scott, D. T., Taylor, K. J. W., Katz, K. H., Schneider, K. C., Makuch, R. W., Oh, W., Vohr, B., et al. (1994) · Pediatrics · doi:10.1542/peds.93.4.543 · Cited by 385
Cited by
Brok, J., Thorlund, K., Wetterslev, J., & Gluud, C. (2009) · International Journal of Epidemiology · doi:10.1093/ije/dyn188 · Cited by 917
Patent Ductus Arteriosus of the Preterm Infant
Hamrick, S. E. G., & Hansmann, G. (2010) · Pediatrics · doi:10.1542/peds.2009-3506 · Cited by 543
Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants
Fowlie, P. W., Davis, P. G., & McGuire, W. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000174.pub2 · Cited by 480
Self-citationClinical Microbiology of Bacterial and Fungal Sepsis in Very-Low-Birth-Weight Infants
Kaufman, D., & Fairchild, K. D. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.3.638-680.2004 · Cited by 435
Towards rational management of the patent ductus arteriosus: the need for disease staging: Table 1
McNamara, P. J., & Sehgal, A. (2007) · Archives of Disease in Childhood - Fetal and Neonatal Edition · doi:10.1136/adc.2007.118117 · Cited by 384
Metadata
- Authors
- Fowlie, P. W., & Davis, P. G.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2002-07-22
- Issue
- 2
- Pages
- CD000174-CD000174
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W2410422786
- Cited by
- 179
- References
- 1
- Type
- reference entry
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. https://app.cochat.ai/papers/10.1002/14651858.cd000174
- The paper
- Fowlie, P. W., & Davis, P. G. (2002). Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd000174
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.